JAM
FOLD

JW Asset Management’s Amicus Therapeutics FOLD Stock Holding History

JW Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-20,000
Closed -$148K – 41
2016
Q3 		$148K Hold
20,000
– – 0.1% 33
2016
Q2 		$109K Hold
20,000
– – 0.09% 32
2016
Q1 		$169K Hold
20,000
– – 0.11% 32
2015
Q4 		$194K Buy
+20,000
New +$180K 0.07% 35

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

JW Asset Management's FOLD Position: Q4 2016 in Review

JW Asset Management sold out of Amicus Therapeutics (FOLD) in Q4 2016, closing a stake of 20,000 shares — an estimated $148K sold.

JW Asset Management first reported a position in FOLD in Q4 2015 and held it in 4 quarters. The position peaked at $194K in Q4 2015. 135 funds tracked by Wall St. Rank hold FOLD as of Q4 2016.

  • JW Asset Management reported no remaining Amicus Therapeutics position as of Q4 2016 after selling out during the quarter.
  • JW Asset Management sold 20,000 Amicus Therapeutics shares in Q4 2016, an estimated $148K.
  • JW Asset Management first reported a position in Amicus Therapeutics in Q4 2015 and held it in 4 quarters.
  • JW Asset Management's Amicus Therapeutics position peaked at $194K in Q4 2015.
  • 135 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2016.

Based on JW Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.